Similarly, in the breast cancer cell line T‐47D, which is also characterized by HR‐positive and HER2‐negative, the fluorescence intensity of CPP30‐Lipo/CDKACT4 decreased with the increasing dose of palbociclib (Figure S3A–C). Here, ERBB2 is linked to breast cancer.